<DOC>
	<DOCNO>NCT02109029</DOCNO>
	<brief_summary>LY2605541 investigational drug develop treatment diabetes mellitus . This study design understand body handle investigational drug , measure quantity LY2605541 fat tissue . The study two part . It involve intravenous ( IV ) infusion investigational drug procedure measure concentration fat tissue . Both part study conduct participant type 1 diabetes mellitus ( T1DM ) . Part A B study might take 7 week complete .</brief_summary>
	<brief_title>A Study LY2505541 Human Insulin Concentrations Fat Tissue</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Have diagnosis Type 1 Diabetes Mellitus ( T1DM ) base medical history least 1 year prior enrollment Have cpeptide value ≤0.3 nanomoles per liter ( nmol/L ) screen Have serum creatinine value within normal limit screen Have haemoglobin A1c ( HbA1c ) value ≤75 millimoles per mole ( mmol/mol ) ( 9.0 % ) screening Have body mass index ( BMI ) 20.030.0 kilogram per meter square ( kg/m^2 ) , inclusive , screen Have know suspect allergy hypersensitivity LY2605541 , human insulin , sinistrin , related compound component formulation Are woman pregnant lactate Have abnormal blood pressure population determine investigator Have renal insufficiency major renal disorder Have proliferative retinopathy maculopathy Have lipodystrophy Have wind heal disorder prone keloid hypertrophic scar formation Have result screen prothrombin time ( PT ) international normalize ratio ( INR ) test significantly prolong Have fast triglyceride value &gt; 4.52 millimoles per liter ( mmol/L ) ( 400 milligrams/deciliter ( mg/dL ) ) Are receive chronic systemic inhale glucocorticoid receive therapy within 4 week dose Have total daily insulin dose great 1.2 unit per kilogram ( U/kg ) Regular use intend use overthecounter prescription medication nutritional supplement affect blood glucose body 's sensitivity insulin promote weight loss within 14 day prior dose Regular use intend use nonselective beta blocker Regular use intend use monoamine oxidase ( MAO ) inhibitor Are currently participate weight loss program plan course study Are unwilling avoid excessive sun exposure , steam bath , sauna , swim study . Sun cream use sun bath 6month period follow study Are unwilling avoid extensive consumption food contain inulin study 48hour period lead clamp</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>